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Abstract
Analyzing the growth of fibrosarcoma lines derived from IL-1α–, IL-1β–, or IL-1αβ–knockout (−/−) mice in the
immunocompetent host revealed that tumor-derived IL-1α and IL-1β exert strong and opposing effects on immune
response induction, which prohibited the evaluation of a potential impact on tumorigenicity. Therefore, in vivo
growth of IL-1–deficient tumor lines was evaluated in nu/nu mice and was compared with in vitro growth charac-
teristics. All IL-1–deficient fibrosarcoma lines grow in immunocompromised mice. However, IL-1α−/−β–competent
(comp) lines grow more aggressively, efficiently induce angiogenesis, and recruit inflammatory cells. Despite
stronger tumorigenicity of IL-1βcomp lines, IL-1α strengthens anchorage-independent growth, but both IL-1α and
IL-1β support drug resistance. Corresponding to the aggressive growth, IL-1βcomp cells display increased matrix
adhesion, motility, and cable formation on matrigel, likely supported by elevated αv/β3 and matrix metallo-
proteinase expression. Recruitment of myeloid cells requires IL-1β but is regulated by IL-1α, because inflammatory
chemokine and cytokine expression is stronger in IL-1α−/−βcomp than in IL-1wt lines. This regulatory effect of tumor-
derived IL-1α is restricted to the tumor environment and does not affect systemic inflammatory response induc-
tion by tumor-derived IL-1β. Both sarcoma cell–derived IL-1α and IL-1β promote tumor growth. However, IL-1α
exerts regulatory activity on the tumor cell–matrix cross-talk, and only IL-1β initiates systemic inflammation.
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Introduction
The IL-1 family consists of the agonistic proteins IL-1α and IL-1β
and the IL-1 receptor antagonist (IL-1Ra) [1,2], which by binding
to IL-1 receptors without transmitting an activation signal acts as
a physiological inhibitor [3]. IL-1α and IL-1β are synthesized as
31-kDa precursors and are processed by proteases to their mature
17-kDa forms. IL-1β–converting enzyme cleaves the inactive IL-1β
precursor; ProIL-1α is processed by calpain [4,5].
Many cell types produce and secrete IL-1α, IL-1β, and IL-1Ra
on activation with environmental stimuli [6,7]. Mononuclear cells
secrete the highest levels, mainly of IL-1β [1,7]. Secreted IL-1α
and IL-1β bind to the same receptors and exert similar biologic
activities. However, IL-1α and IL-1β differ inasmuch as IL-1β is
solely active as a secreted product; IL-1α is mostly active as an intra-
cellular precursor and in its membrane-associated form. The active
membrane form of IL-1α is derived from myristoylation of proIL-
1α and is anchored to the membrane through a mannose-like re-
ceptor [1,2,7–9].
IL-1 is a pleiotrophic cytokine that primarily affects inflammatory
responses, immune reactivity, and hematopoiesis [1,2,7,9,10]. Its
potency stems from inducing cytokine, chemokine, proinflammatory
molecule secretion, and adhesion molecule expression in diverse cells,
thereby amplifying and sustaining the response. Both the localiza-
tion of the IL-1 molecules in the producing cell and the microenvi-
ronment dictate their biologic functions [8]. Membrane-associated
IL-1α is supposed to be immunostimulatory. Cytosolic proIL-1α
may control gene expression, proliferation, and differentiation [5,
11–15]. Low-level secreted IL-1β induces limited inflammatory re-
sponses followed by T cell activation. High doses of IL-1β are ac-
companied by broad inflammation with tissue damage [1,2,7,16].
IL-1 is abundant at tumor sites, being secreted by the malignant
cells and/or cells in the tumor microenvironment in response to local
inflammatory signals. It can promote invasiveness and metastasis
formation or induce an antitumor immune response and inhibit
tumor growth [6,7,17]. Over-expression of the precursor of IL-1α
by fibrosarcoma cells can initiate a strong immune response [11–
13,15,18]. In contrast, IL-1β–transfected tumor cells are more inva-
sive than wild type cells [19,20]. Increased invasiveness correlates
with enhanced angiogenesis and activation of immunosuppression
[18–23], which may be a consequence of tumor-derived IL-1β sup-
porting extramedullary myelopoiesis [18,23,24].
To explore whether these effects are exclusively or at least pre-
dominantly due to tumor-derived IL-1, fibrosarcoma were induced
in IL-1α–, IL-1β–, or IL-1αβ–deficient mice [19,25]. Because IL-1
expression and secretion was unimpaired in the syngeneic host, this
system allowed to selectively elaborate the contribution of tumor-
derived IL-1 on tumor growth. The analysis of in vivo growth of these
IL-1α–, IL-1β–, or IL-1αβ–deficient lines in the immunocompetent,
IL-1–competent host confirmed that tumor-derived IL-1 induces an
utmost strong T cell response (IL-1α) or immunosuppression (IL-1β)
[26]. Thus, it became important to explore whether tumor-derived
IL-1 affects exclusively the host’s immune system or also the tumor
cell itself. A detailed in vitro analysis of the tumor lines and their
growth in nu/nu mice revealed that IL-1β comp tumors are more ag-
gressive, which is a consequence of tumor-derived IL-1β locally and
systemically initiating an inflammatory milieu. Tumor-derived IL-
1α exerts no systemic effects, but promotes transcription of genes,




nu/nu mice (WIGA, Sulzfeld, Germany), kept under specific
pathogen-free conditions, fed sterilized food, and water ad libitum,
were used for experiments at the age of 8 to 10 weeks. IL-1RI−/− mice
were purchased from Jackson Laboratories (Bar Harbor, ME). Fi-
brosarcoma were induced by 3-methylcholanthrene treatment of
wt, IL-1α−/−, IL-1β−/−, IL-1αβ−/−, and IL-1RI−/− C57BL6 mice [19].
The IL-1–deficient mice were generously provided to R.N. A. by
Prof. Yoichiro Iwakura, University of Tokyo, Tokyo, Japan [25]. 3-
Methylcholanthrene (Sigma Israel, Rehovot, Israel) was dissolved in
olive oil (200 μg/mouse) and was subcutaneously (s.c.) injected into
the right thigh [27]. Local fibrosarcomas developed within 3 to
5 months. When tumors reached a diameter of 10 mm, mice were
killed and the tumor tissue was aseptically removed. Part of the tissue
was processed for the establishment of cell lines by enzymatic diges-
tion in trypsin. The following fibrosarcoma lines were used: IL-1wt
lines 2, 19, 21 (wt2, wt19, wt21), IL-1α−/− lines 3, 15, 16 (α−/−3,
α−/−15, α−/−16), IL-1β−/− lines 3, 4, 17 (β−/−3, β−/−4, β−/−17),
IL-1αβ−/− lines 6, 11, 13 (αβ−/−6, αβ−/−11, αβ−/−13), and IL-1RI −/−
lines PV and R1. Each of these 14 tumor lines was derived from a dif-
ferent 3-methylcholanthrene–treated C57BL6 mouse. The lines were
maintained in RPMI 1640, 10% fetal calf serum.
Antibodies
Anti-CD11b, -CD54 (European Collection of Animal Cell Cul-
tures, Salisbury, UK), -panCD44 (American Type Culture Collec-
tion, Manassas, VA), CD49d [28], -CD44v6, -CD51, -CD49c,
-CD49f, -CD29, -CD61, -CD154, -CD31 (PECAM), -CD62E
(E-selectin), CD105 (endoglin), -Gr-1, -CD95, -CD178 (CD95L),
-CD120a (TNFRI), -CD120b (TNFRII), -CD121a (IL-1RI),
-CD121b (IL-1RII), -CD87 (uPAR), -MMP2, -CCL1, -CCL2,
-CCL3, -CCL5, -CCL15, -CCL17, -CCL19, -CCL20, -CXCL10,
-OPN, -CCR3, -CCR4, -CCR6, -CCR7, -CCR8, native and bio-
tinylated anti–IL-1α, –IL-1β, –IL-4, –IL-6, –IL-10, –IL-12, -IFNγ,
-TNFα, -TGFβ, -ERK1,2, -pERK1,2, -pJNK, -pJun, -PTEN,
-pIκBα, -pAkt, -pBAD, -Bid, -BIM, -Bcl-2, –Bcl-Xl, -BAX, -PARP,
-actin, and secondary labeled [biotin, fluorescein isothiocyanate
(FITC), phycoerythrin, allophycocyanin, and HRP] antibodies, were
obtained commercially.
Flow Cytometry
Approximately 2.5 to 5 × 105 cells were stained according to stan-
dard protocols. For intracellular staining, cells were fixed (formal-
dehyde) and permeabilized (PBS, 1% Tween 20). Apoptosis was
determined by Annexin V–FITC/PI staining. Fluorescence was de-
termined using a FACStar and the CellQuest program (BD, Heidel-
berg, Germany).
Cytokine ELISA
Standard sandwich ELISA procedures were used to measure IL-1α,
IL-1β, and IL-1Ra secretion.
Immunohistology
Sections (5 μm) of snap-frozen tumor were fixed (chloroform/
acetone, 1:1, 4 minutes) and treated with levamisole solution to
ablate tissue alkaline phosphatase activity. Nonspecific binding was
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blocked using an avidin-biotin blocking kit (Vector Laboratories,
Burlingame, CA) and 2% normal serum from the same species as
the secondary antibodies. For intracellular staining, tissues were fixed
and permeabilized (4% paraformaldehyde, 0.1% Triton X-100).
Tissues were incubated with the primary antibody (1 hour), the bio-
tinylated secondary antibodies (30 minutes), and alkaline phosphatase–
conjugated avidin-biotin complex solutions (5–20 minutes). Sections
were counterstained with Mayer’s hematoxylin. Primary antibodies
were replaced by rat or rabbit IgG for negative controls.
Western Blot Analysis
Cells (5 × 105) were lysed in 1% Triton X-100. Where indicated
cells were cultured for 24 hours in the presence of recombinant
IL-1α and/or IL-1β (10 ng/ml) (CyoLAB/Peprotech, Rocky Hill,
NJ). Lysates were resolved on 10% SDS-PAGE under reducing con-
ditions. Proteins were transferred to nitrocellulose membranes (30 V,
overnight). After blocking (5% fat-free milk powder, PBS, 0.1% Tween
20), immunoblot analysis was performed with the indicated anti-
bodies, followed by HRP-labeled secondary antibodies. Blots were
developed with the enhanced chemiluminescence detection system.
Tumor Cell Proliferation and Apoptosis
Tumor cells (1 × 104) were seeded in F-bottom 96-well plates,
adding 10 μCi/ml 3H-thymidine and harvesting cultures after
16 hours. Apoptosis resistance was evaluated by the MTT assay
and by Annexin V–FITC/PI staining. Cells (1 × 105), cultured over-
night in F-bottom 96-well plates, were grown for 3 days in RPMI-s
containing serial dilutions of cisplatin [cis-diamineplatinum(II) di-
chloride; Sigma, Munich, Germany], starting with 35 μg/ml.
Adhesion Assay
Cells (1 × 105) were seeded on F-bottom 96-well plates coated
with collagens I and IV (10 μg/ml) or vitronectin (2 μg/ml). After
2 hours (37°C, 5% CO2), nonadherent cells were removed by wash-
ing, and adherent cells were stained with crystal violet. Absorbance
was measured at 595 nm.
Soft Agar Assay
Tumor cells, suspended in 0.3% agar, were seeded on a pre-
formed 1% agar layer. Where indicated, the agar contained 10 μg/
ml anti–IL-1RI. Colonies was counted at an inverted microscope
after 3 weeks.
Migration Assays
Tumor cells were seeded in 2-cm diameter, fibronectin-coated
Petri dishes. Subconfluent cultures were wounded by scratching with
a micropipette tip, washed, and incubated for 48 hours. Wound heal-
ing was evaluated microscopically after staining with hematoxylin-
eosin. Alternatively, tumor cells (1 × 104) were seeded in the upper
part of a Boyden chamber in 30 μl of RPMI/0.1% BSA. The lower
part of the chamber, separated by an 8-μm–pore size polycarbonate
membrane (Neuroprobe, Gaithersburg, MD), contained 30 μl of
RPMI/10% fetal calf serum. After 4 hours, cells on the lower side
of the membrane were stained with crystal violet. Absorbance was
measured at 595 nm.
Zymography
Tumor cells (5 × 105) were starved for 24 hours, the conditioned
medium was centrifuged (15 minutes, 15,000g), and aliquots of the
supernatants were incubated with Lämmli buffer (15 minutes, 37°C)
and separated in a 10% acrylamide gel containing 1 mg/ml gelatin.
After washing, gels were stained with Coomassie blue.
Matrigel Assay
Tumor cells (2 × 105) were seeded on matrigel-coated 24-well plates.
Cable formation was evaluated after 24 hours by light microscopy.
Tumor Growth
nu/nu mice received 5 × 105 tumor cells, s.c. Tumor growth was
controlled (mean diameter) twice per week. Mice were killed at the
indicated time points after tumor cell application, but latest when the
s.c. tumor mass reached a mean diameter of 3 cm (survival time).
Mice were bled by eye puncture, and serum was collected. Tumor,
spleen, femura, and tibiae were excised. The tumor was shock frozen.
The spleen was teased through fine gauze. The bones were flushed
with PBS. Single spleen cell (SC) and bone marrow cell (BMC) sus-
pensions were washed and used for flow cytometry. Animal experi-
ments were approved by the governmental authorities for animal
health care.
Statistical Analysis
Significance of differences was calculated by the Student’s t-test
(in vitro assays) or the Wilcoxon rank sum test (in vivo assays).
P values <.05 were considered significant.
Results
Using fibrosarcoma lines derived from IL-1α−/−, IL-1β−/−, and IL-
1αβ−/− mice, we recently demonstrated that tumor-derived IL-1α
and IL-1β have very strong bearing on immune response induction
in the immunocompetent, IL-1–competent host, such that IL-1αcomp
tumor lines induce a T cell–mediated rejection response, whereas
IL-1β comp tumors induce strong immunosuppression that suffices
to counterregulate immune response induction by IL-1α with the
consequence that IL-1αβ comp tumors grow in the immunocompetent
host [26]. These unexpectedly strong effects exclusively of tumor-
derived IL-1 on the host immune system prohibited a judgment
on the impact of tumor-derived IL-1 on tumorigenicity. However,
an answer to this question is essential for estimating potential thera-
peutic efficacy of IL-1α in tumor rejection.
Tumorigenicity of IL-1α– and/or IL-1β–Deficient
Tumor Cells
IL-1αcompIL-1β−/− tumor lines do not grow in the immuno-
competent host [26]. To elaborate whether this failure to grow is ex-
clusively a consequence of induction of a potent T cell–mediated
response or whether IL-1αcompIL-1β−/− tumor lines are less tumori-
genic, the experiment was repeated in nu/nu mice.
All tumor lines grew in nu/nu mice. However, the growth rate of
IL-1β−/− and IL-1αβ−/− tumors was reduced, and accordingly, the
mean survival time was prolonged (Figure 1, A and B). In addition,
IL-1β comp tumors grew more aggressively, infiltrated the surrounding
tissue, and showed massive infiltration by myeloid cells, which were
not seen in IL-1β−/− tumors (Figure 1C ) but have also been seen in
IL-1β comp tumors in the immunocompetent host [26]. Importantly,
too, IL-1β comp tumors strongly supported angiogenesis, whereas only
few capillaries were detected in IL-1β−/− tumors (Figure 1D).
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Figure 1. Growth of wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma lines in nu/numice. (A and B) nu/numice (10 mice/line) received a
s.c. injection of 5 × 105 fibrosarcoma cells from 3 wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma lines. (A) Starting 7 days after
tumor cell inoculation, tumor growth was monitored twice per week by measuring the tumor diameter. The mean tumor diameter ±
SD of 30 mice/group (10 mice/line) is shown. (B) Mice were sacrificed when the mean tumor diameter reached 3 cm (survival time). The
mean survival time ± SD (30 mice/group; 10 mice/line) is shown. Significant differences in the mean tumor diameter and the survival
time as compared to mice receiving wt clones are indicated by an asterisk. (C and D) Wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma
cells (5 × 105) were s.c. implanted into nu/numice. Tumors of a mean diameter of 0.5 cm were excised, shock frozen and 5 μm sections
were stained with anti–Gr-1 (C) and anti-CD31 (D). Representative examples of one wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma
lines are shown. (E) IL-1α, IL-1β, and IL-1Ra expression and secretion was evaluated in lysates (corresponding to 1 × 105 cells)
and culture supernatants (fresh medium being added to subconfluent cultures and being collected after 24 hours) of wt, IL-1α−/−,
IL-1β−/−, IL-1αβ−/−, and IL-1RI−/− fibrosarcoma lines by ELISA. Secreted IL-1α hardly could be detected in any of the tested lines.
Yet, even in supernatants and lysates of IL-1wt and IL-1RI−/− cells, IL-1α and IL-1β was too low for a reliable quantification. Therefore,
extinction values (mean ± SD of triplicates) are shown. Background values have been subtracted.
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Taken together, irrespective of IL-1 expression, 3-methylcholanthrene–
induced fibrosarcoma are tumorigenic in the immunocompromised
host. However, tumor-derived IL-1β appears to promote tumor
growth more efficiently than tumor-derived IL-1α. Notably, the
tumors express/secrete a very low level of IL-1α and IL-1β, and there
is no evidence that the absence of IL-1α or IL-1β would be compen-
sated by considerably up-regulated expression/secretion of the re-
maining IL-1 gene. IL-1 expression was also low in an IL-1RI−/−
line. IL-1Ra expression and, particularly, secretion were slightly in-
creased in IL-1α−/−β comp lines and slightly reduced in IL-1β−/− lines.
It was not influenced by an IL-1RI deficiency (Figure 1E ). These
findings suggested that low-level tumor-derived IL-1 or the host en-
vironment during carcinogenesis may have strong bearing on the
expression of distinct genes. To control for these hypotheses, we evalu-
ated several central features of tumorigenicity and tumor aggres-
siveness in the wt, IL-1α−/−, IL-1β−/−, and IL-1α/β−/− tumor lines.
To avoid, as far as possible, in vitro selection processes, the experi-
ments were performed with uncloned tumor lines that were cultured
for less than 10 passages in vitro. Furthermore, each line was derived
from a different 3-methylcholanthrene–treated mouse.
IL-1α Competence Promotes Anchorage-Independent
Growth and Both Tumor-Derived IL-1α and IL-1β
Support Apoptosis Resistance
The accelerated growth of IL-1β comp tumors could have been a
consequence of accelerated cell cycle progression or pronounced
apoptosis resistance. Therefore, we explored the impact of IL-1 com-
petence on these parameters in vitro. We expected accelerated prolif-
eration and/or high-efficacy anchorage-independent growth possibly
combined with increased apoptosis resistance of IL-1β comp lines. This
has not been the case.
Neither an IL-1β nor an IL-1α deficiency influenced tumor cell
proliferation (Figure 2A). In addition, IL-1α, but not IL-1β com-
petence, supported anchorage-independent growth in soft agar,
such that colony formation of IL-1α−/− lines was strongly reduced.
Anchorage-independent growth of IL-1αβ−/− lines also was impaired,
but less efficiently. The high cloning efficacy of IL-1αcomp lines was
maintained in the presence of anti–IL-1RI. In addition, an IL-1RI−/−
line also revealed high cloning efficacy. However, the low cloning
efficacy of IL-1α−/−β comp lines was further reduced in the presence
of anti–IL-1RI (Figure 2B). Thus, IL-1α supports anchorage in-
dependent growth likely independent of IL-1RI expression, but
IL-1β (minor contribution, if at all) might act through the IL-1RI.
Apoptosis/drug resistance of the IL-1–deficient lines also did not
meet our expectation. When cultured in the presence of an increas-
ing dose of cisplatin, apoptosis resistance was strongly reduced in
IL-1α−/− and IL-1β−/− cells, whereas IL-1αβ−/− cells displayed un-
altered or slightly increased cisplatin resistance compared with wt
cells. This has been evaluated by MTT (Figure 2C ) and Annexin
V/PI staining (Figure 2D) and has been confirmed by reduced 3H-
thymidine uptake of cisplatin-treated IL-1α−/− and IL-1β−/−, but not
IL-1αβ −/− compared with IL-1wt cells (data not shown).
Trying to explain these unexpected findings, expression of several
pro- and antiapoptotic proteins was analyzed by flow cytometry and
Western blot analysis. CD95 expression was reduced in IL-1α−/−,
IL-1β−/−, and IL-1αβ−/− sarcoma lines (Figure 2E ). Expression of
CD95L and TNFRI was largely independent of tumor cell–associated
IL-1. Instead, TNFRII expression was particularly low in IL-1α−/− and
IL-1αβ−/− lines (Table 1). Expression of some proapoptotic proteins,
such as BIM, PARP (data not shown), and Bid, varied between the
individual lines and thus could not account for the uniformly de-
creased apoptosis resistance of IL-1α−/− and IL-1β−/− lines. However,
in line with unimpaired drug resistance, both Bcl2 and proapoptotic
Bax expression was significantly increased in IL-1αβ−/− lines. De-
creased apoptosis resistance of IL-1β−/− lines was accompanied by
reduced Bcl2 expression. In IL-1α−/− lines, a reduction in Bcl2 expres-
sion was not consistently observed (Figure 2F ). These findings suggest
that IL-1α and IL-1β might be distinctly involved in the regulation
of both pro- and antiapoptotic signaling cascades. To support this
hypothesis, Bcl2 and Bax expression was evaluated after culturing cells
in the presence of recombinant IL-1α and/or IL-1β. Recombinant
IL-1α and IL-1β did not influence Bax expression. This also ac-
counted for an IL-1RI−/− line. Surprisingly, Bcl2 expression became
up-regulated in the presence of exogeneous IL-1α plus IL-1β in the
IL-1RI−/− line and down-regulated in an IL-1αβ−/− line. Instead, exoge-
neous IL-1α or IL-1β had no impact on Bcl2 expression in IL-1wt,
IL-1α−/−, and IL-1β−/− cells (Table 2). Thus, one could hypothesize
that possibly in the absence of IL-1α and IL-1β the Bcl2 protein
may become stabilized or, at least, become less efficiently degraded.
So far, we failed to identify the relevant signaling pathways. How-
ever, several pathways could be excluded. Akt phosphorylation and Pten
expression were not or not consistently affected by an IL-1α or IL-1β
deficiency. In addition, extracellular-regulated kinase 1/2 (ERK1/2)
phosphorylation, which could have been indicative for apoptosis resis-
tance and anchorage independence [29], was not affected by an IL-1α
and/or IL-1β deficiency (Figure 2G ).
As a possible alternative explanation for the distinct effect of
tumor-derived IL-1α and IL-1β on tumor cell survival, we hypoth-
esized that IL-1β, possibly together with TNFα, might sustain an
inflammatory milieu that supports the activation of an apoptotic
signaling cascade. To control the latter, inflammatory cytokine ex-
pression was evaluated in the IL-1comp and IL-1−/− tumor lines. Un-
expectedly, IL-10 and TNFα expression was increased in IL-1α−/−
β comp, but also, although less pronounced, in IL-1αβ−/− lines. This
suggests that within the tumor cell inflammatory cytokines expres-
sion may be actively controlled and down-regulated by IL-1α. In line
with this interpretation, inflammatory cytokine expression was com-
parably low in IL-1αcomp, IL-1RI−/− lines (Figure 2H ). It should be
mentioned that IL-1RI expression was unaltered in IL-1−/− cells
and IL-1RII expression was low and not significantly influenced by
tumor-associated IL-1 (data not shown).
Although these experiments confirm opposing effects of IL-1α
and IL-1β on pro- and antiapoptotic gene expression by the IL-1–
producing tumor cell and an involvement of IL-1α in proinflam-
matory cytokine expression, we have no unequivocal answer on
the impact of tumor-derived IL-1α and IL-1β on the tumor cell’s
apoptosis resistance. In addition, only IL-1α promotes anchorage-
independent growth, possibly through sustained TNFRII expression
[30]. Both apoptosis resistance, distinctly regulated by tumor-derived
IL-1α and IL-1β and anchorage-independent growth promotion by
IL-1α, do not explain accelerated tumor growth of IL-1β comp tumor
lines in vivo.
Tumor Cell–Derived IL-1α and IL-1β: Cell Adhesion,
Migration, and Angiogenesis
IL-1β−/− fibrosarcoma lines grow less invasively and are poorly
vascularized. We interpreted the finding in the sense that tumor-
derived IL-1β might modulate tumor cell adhesion, migration,
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matrix degradation, and angiogenesis. To support the assumption,
adhesion molecule, matrix metalloproteinase (MMP), and chemo-
kine expression was analyzed.
From the adhesion molecules tested, that comprised panCD44,
CD44v6, the integrins CD49c (α3), CD49d (α4), CD49f (α6),
CD51 (αv), CD29 (β1), CD61 (β3), CD104 (β4), CD54 (ICAM1),
and CD62E (E-selectin), reduced CD51 and CD61 expression in
IL-1β−/− lines was the most prominent change. CD44v6 and CD54
were up-regulated in IL-1αcompβ−/− lines. CD62E was up-regulated in
IL-1α−/−βcomp and down-regulated in IL-1αcompβ −/− lines (Figure 3A).
Additional changes in adhesion molecule expression were not signifi-
cant (data not shown).
Reduced CD51/CD61 expression of IL-1β −/− and IL-1αβ −/− cells
correlates with reduced adhesion to collagens I and IV and vitro-
nectin (Figure 3B). Adhesion to hyaluronan, collagen III, fibronectin,
and laminins 1 and 5 was unaltered (data not shown). IL-1β −/− and
IL-1αβ−/− tumor cells also revealed reduced transwell migration and
in vitro wound healing (Figure 3, C and D). In line with the reduced
CD51/CD61 expression, IL-1β−/− and IL-1αβ−/− tumor cells formed
small clusters but not cablelike structures on matrigel. Instead, IL-
1β comp lines formed a net of cablelike structures (Figure 3E ).
Cable formation is suggested to be an angiogenesis-related morpho-
genic feature. Thus, cable formation by IL-1β comp tumor lines corre-
sponds well to the stronger in vivo angiogenesis by these tumors, and
it became interesting to see whether IL-1β would have bearing on
additional angiogenesis-related factors. Vascular endothelial growth
factor and basic fibroblast growth factor expression was low and was
not reduced in IL-1β−/− or IL-1αβ−/− lines (data not shown). Instead,
in the absence of IL-1β, low uPAR expression was further reduced
(Figure 3F ), and MMP9 secretion was strongly diminished in IL-
1αcompβ−/− and distinctly in IL-1αβ−/− lines (Figure 3G ).
Taken together, IL-1β comp tumor lines are more adhesive and
motile and display angiogenesis-related features. These findings are
in line with high CD51/CD61, up-regulated CD62, up-regulated
uPAR expression, and increased MMP provision. Neither was there
evidence for an active contribution of tumor-derived IL-1α to CD51/
CD61, uPAR, and MMP expression/secretion nor has there been evi-
dence that IL-1α may counterregulate expression of these molecules.
As outlined previously, this was distinct for cytokines but is also
distinct for chemokine expression. A deficiency in IL-1α or IL-1β
had no negative impact on chemokine secretion by the tumor cells.
On the contrary, the expression of CCL2, CCL3, CCL5, CCL15,
CCL19, and OPN, chemokines preferentially attracting leukocytes
[31], was increased in IL-1α−/− tumor lines, indicating that IL-1α
Figure 2. Tumor cell–associated IL-1, proliferation, anoikis, and apoptosis resistance. (A) Three wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/−
fibrosarcoma lines (2 × 104 cells) were grown for 16 hours in RPMI in the presence of 10 μCi of 3H-thymidine and incorporation
was determined in a β-counter. (B1) Three wt, IL-1α
−/−, IL-1β−/−, IL-1αβ−/− and 2 IL-1RI−/− fibrosarcoma lines (102 cells) were suspended
in 0.3% agar and seeded on a 1% agar layer. Where indicated, cultures contained 10 μg/ml anti–IL-1RI. After 3 weeks of culture, colonies
were counted. (B2) Representative examples for one wt, IL-1α
−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma lines are shown. (C and D) Three
wt, IL-1α−/−, IL-1β−/− and IL-1αβ−/− fibrosarcoma lines (1 × 105 cells) were cultured for 48 hours in the presence of 1.56 to 25 μg
cisplatin. Survival was evaluated by MTT staining (C) and Annexin V–FITC/PI staining (D). The percentage of live cells (C) and apoptotic
cells (D) as compared to cells grown in the absence of cisplatin (100%) is shown (mean values of triplicates). The amount of cisplatin
required for a 50% reduction in cell survival is indicated. (E) CD95 expression was evaluated on three wt, IL-1α−/−, IL-1β−/−, and IL-
1αβ−/− fibrosarcoma lines by flow cytometry. The percentage of stained cells and the mean intensity of staining is shown. (F and G)
Wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma cells were lysed. Lysates were separated by SDS-PAGE. After transfer, membranes
were blotted with the indicated antibodies specific for pro- and antiapoptotic proteins and for pro- and antiapoptotic signal transducing
molecules. For Bcl2 and Bax, the intensity ratio in comparison to the actin loading control is indicated. One of 3 representative experi-
ments are shown. (H) Three wt, IL-1α−/−, IL-1β−/−, IL-1αβ−/−, and 2 IL-1RI−/− fibrosarcoma lines were tested for cytokine expression by
flow cytometry. The mean percentage of stained cells is shown: (A, B1, C, D, E, and H) mean ± SD of the distinct lines are presented
and significant differences between wt, IL-1α−/−, IL-1β−/−, IL-1αβ−/−, and IL-1RI−/− lines are indicated by an asterisk, a reduction in
colony formation (B1) by anti–IL-1RI is indicated by a boldface “s.” Experiments were repeated two to three times and revealed com-
parable results.
Table 1. Flow Cytometry Analysis of Apoptosis Marker Expression in wt, IL-1α−/−, IL-1β −/−, and
IL-1αβ −/− Fibrosarcoma Lines.
Marker Tumor Lines (P )
wt α−/− β−/− αβ−/−
CD95
% stained cells 41.2 ± 4.3 29.2 ± 1.7 (.011) 19.4 ± 1.8 (.001) 17.5 ± 1.1 (<.0001)
Mean intensity of
expression*
42.0 ± 1.0 32.3 ± 2.5 (.004) 23.0 ± 2.6 (<.001) 19.3 ± 1.5 (<.0001)
CD95L
% stained cells 4.3 ± 0.6 3.5 ± 0.5 (ns) 2.3 ± 0.2 (.006) 4.6 ± 0.7 (ns)
Mean intensity of
expression*
11.7 ± 0.6 13.0 ± 2.0 (ns) 11.0 ± 0.1 (ns) 12.3 ± 0.6 (ns)
CD120a, TNFRI
% stained cells 15.0 ± 0.9 14.4 ± 1.3 (ns) 13.9 ± 1.0 (ns) 16.6 ± 1.7 (ns)
Mean intensity of
expression*
21.3 ± 1.2 20.3 ± 1.5 (ns) 19.3 ± 1.5 (ns) 23.3 ± 2.1 (ns)
CD120b, TNFRII
% stained cells 19.6 ± 2.1 12.0 ± 2.2 (.012) 15.4 ± 2.7 (ns) 12.0 ± 1.1 (.005)
Mean intensity of
expression*
28.7 ± 4.5 16.3 ± 2.3 (.014) 21.0 ± 5.3 (ns) 15.7 ± 0.6 (.008)
*Negative controls were set to a mean intensity of 10.
Table 2. Regulation of Bcl2 and Bax By Recombinant IL-1 in IL-1αβ −/− and IL-1RI −/− Lines.
Marker Recombinant IL-1 Ratio Marker/Actin*
wt2 IL-1α−/−3 IL-1β−/−3 IL-1αβ−/−11 IL-1RI−/−1
Bcl2 None 0.25 0.25 0.10 1.00 0.50
IL-1α 0.35 0.35 0.15 0.75 0.60
IL-1β 0.25 0.35 0.10 0.50 0.60
IL-1α + IL-1β 0.30 0.35 0.10 0.45 1.2
Bax None 0.40 0.35 0.35 0.75 1.00
IL-1α 0.55 0.30 0.40 0.80 1.00
IL-1β 0.45 0.30 0.35 0.60 1.10
IL-1α + IL-1β 0.40 0.30 0.30 0.50 1.15
Cells were cultured for 24 hours in the presence of 10 ng/ml recombinant IL-1.
*Strong differences in the marker/actin ratio are indicated in bold.
Neoplasia Vol. 10, No. 6, 2008 Fibrosarcoma-derived IL-1 Nazarenko et al. 555
556 Fibrosarcoma-derived IL-1 Nazarenko et al. Neoplasia Vol. 10, No. 6, 2008
may counterregulate expression-promoting activities. A distinct ef-
fect was only seen on T cell attracting CCL20 and CXCL10 expres-
sion [32,33] that was reduced in IL-1α−/−β comp and was high in
IL-1αcompβ−/− cells (Figure 4A).
The impact of IL-1α and IL-1β on chemokine receptor expression
was less pronounced. Expression of the chemokine receptors CCR3
and CCR8 was not significantly influenced by tumor-associated
IL-1α and IL-1β. Instead, CCR4 and, most pronounced, CCR6 ex-
pression was enhanced in IL-1α−/−β comp lines, which could indicate
a negative feedback of IL-1α on IL-1β–induced CCR4 and CCR6
expression, with high CCR6 expression also being described for
metastatic tumor cells [34]. As could have been expected, CCR7, a
chemokine receptor on inflammatory fibroblasts [35], was hardly ex-
pressed in IL-1β−/− and IL-1αβ−/− clones (Figure 4B).
Thus, mostly IL-1α−/−β comp lines displayed up-regulated expres-
sion of leukocyte attracting chemokines and of CCR6, a chemokine
receptor that has been described to support angiogenesis and meta-
static spread. Because, in many instances, expression of inflammatory
chemokines becomes up-regulated in the absence of IL-1α, we inter-
pret the finding in the sense that in wt fibrosarcoma cells, IL-1α
counterregulates not only inflammatory cytokine but also inflamma-
tory chemokine induction. This implies that tumor-derived IL-1α
actually could hamper the aggressiveness of IL-β comp tumors. In line
with this interpretation, IL-1α−/−β comp tumor lines grew faster and
Figure 3. Tumor-associated IL-1, matrix adhesion, migration, and angiogenesis induction. (A–G) Three wt, IL-1α−/−, IL-1β−/−, and
IL-1αβ−/− fibrosarcoma lines were tested for the following: (A) Adhesion molecule expression by flow cytometry. The percentage of
stained cells and the mean intensity of staining are shown. (B) Adhesion to components of the extracellular matrix. Adhesion was mea-
sured after a 2-hour incubation by crystal violet staining. (C) Transwell migration, evaluated after a 4-hour incubation by crystal violet
staining. (D) Migration into a wounded monolayer 48 hours after wounding. A representative example of one wt, IL-1α−/−, IL-1β−/−, and
IL-1αβ−/− fibrosarcoma line is shown. (E) Cable formation on matrigel evaluated after 24 hours. (F) uPAR expression was evaluated
by flow cytometry. The percentage of stained cells and the mean intensity of staining are shown. (G) MMP2 and MMP9 expression
in 3 wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma lines as revealed by zymography. (A–C and F) Mean ± SD of three distinct lines
are presented, and significant differences between wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− lines are indicated by an asterisk. All experi-
ments were repeated at least three times and revealed comparable results.
Figure 4. Tumor cell–associated IL-1, chemokine, and chemokine receptor expression. (A and B) Three wt, IL-1α−/−, IL-1β−/−, and
IL-1αβ−/− fibrosarcoma lines were tested for (A) chemokine and (B) chemokine receptor expression by flow cytometry. The percentage
of stained cells is shown. Mean values ± SD of 3 distinct lines are presented, and significant differences between wt, IL-1α−/−, IL-1β−/−,
and IL-1αβ−/− lines are indicated by an asterisk. The experiments were repeated three times and revealed comparable results.
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more aggressive than IL-1wt lines. However, IL-1αβ−/− lines grew slower
than IL-1wt lines. Thus, tumor-derived IL-1β may exert an additional,
IL-1α–independent, systemic effect on the tumor-bearing host.
Systemic Activity of Tumor-Derived IL-1β
IL-1α and IL-1β are proinflammatory cytokines, the potency of
IL-1 originating from its ability to induce cytokine and chemokine
expression [1,2,7,8,16,17]. As outlined previously, cytokine and
chemokine expression within the tumor cell was regulated by
IL-1α, such that inflammatory cytokine and chemokine expression
was strongly increased in IL-1α−/− tumor cells. Accordingly, IL-
1α−/−β comp tumors displayed increased angiogenesis and attracted
myeloid cells more efficiently than IL-1wt tumors (Figure 1, C and
D). However, IL-1αcompβ −/− and IL-1αβ−/− tumors were poorly vas-
cularized and very few myeloid cells were detected. Thus, tumor-
derived IL-1β obviously contributed to the cross-talk between the
tumor and the surrounding.
Indeed, tumor-derived IL-1β strongly influenced myelopoiesis.
The recovery of BMCs and SCs was significantly increased in mice
bearing wt or IL-1α−/−β comp tumors, whereas a moderate increase
only of SC was seen in IL-1αcompβ −/− or IL-1αβ −/− tumor-bearing
nu/nu mice (Figure 5A). The increase in SC was mostly due to
myeloid cells, where up to 25% of IL-1wt or IL-1α−/−β comp tumor-
bearing mice-derived SC expressed the phenotype of myeloid-derived
suppressor cells (Gr-1+CD11b+). In the spleen of tumor-free control
mice, only 4% to 6% of cells are Gr-1+CD11b+ (Figure 5B). Further-
more, in comparison to SC of tumor-free mice, the percentage of
IL-6–, IL-10–, TNFα–, IL-12–, IFNγ–, and IL-1β–expressing
SC was strongly increased in mice bearing IL-1β comp tumors (Fig-
ure 5C ). Furthermore, whereas IL-1β was hardly detectable in the
serum of tumor-free mice (data not shown), an increased amount
of IL-1β was recovered from the serum of IL-1β comp tumor-bearing
nu/nu mice (Figure 5D). None of these phenomena was seen in mice
bearing IL-1αβ−/− tumors. Thus, IL-1β expression on a subcutaneously
Figure 5. Tumor-associated IL-1β, myelopoiesis, and cytokine expression/secretion by leukocytes. Three wt, IL-1α−/−, IL-1β−/−, and
IL-1αβ−/− fibrosarcoma lines (5 × 105 cells) were s.c. implanted into nu/nu mice (3 mice/line). Mice were sacrificed after 4 weeks.
(A) Mean ± SD of the number of BMC and SC from 5 control mice and 9 each wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma-bearing
mice. (B) The percentage of Gr-1+ and of Gr-1+CD11b+ SC was evaluated by flow cytometry. Values represent the mean ± SD from
six tumor-free and tumor-bearing mice per group (2 mice/group wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− fibrosarcoma lines). (C) Cytokine
expression in SC, 4 weeks after tumor cell application, was evaluated by flow cytometry. SC were fixed and permeabilized in advance.
Mean ± SD of SC from 3 tumor-free mice and 3 mice bearing the different wt, IL-1α−/−, IL-1β−/−, and IL-1αβ−/− lines is shown. (D)
Serum was collected from 4-week-old tumor-bearing mice. The relative amount of IL-1β was determined in a sandwich ELISA. Values
represent the mean ± SD of sera from 6 mice (2 mice/line). Significant differences of IL-1α−/−, IL-1β−/−, and IL-1αβ−/− compared with wt
fibrosarcoma-bearing mice are indicated by an asterisk.
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growing tumor exerts a strong systemic effect on leukopoiesis and suf-
fices to create an inflammatory milieu. There was no evidence for a
contribution of tumor-derived IL-1α.
Discussion
IL-1α and IL-1β are pleiotropic cytokines, that despite binding to
the same receptor, can exert distinct effects [1,2,7–9,16]. This relies,
at least in part, on IL-1α mainly being active in the membrane-
bound form and as proIL-1α in the cytoplasm [7,9,15], whereas
IL-1β is secreted and acts on the microenvironment and systemically
[1,2,7–9,16,17]. These distinct activities sufficed for the induction
of a T cell–mediated rejection response against IL-1αcompβ−/− tumors
[26]. On the contrary, IL-1β comp tumors promote an inflammatory
response that leads to the expansion of MDSC and Treg, which
together prevent rejection of IL-1αβ comp tumors. Nonetheless, by
the failure of IL-1αcompβ−/− tumor lines to grow in the immuno-
competent host, the question arose on the feedback impact of
tumor-derived IL-1α and IL-1β on the tumor cell itself. To answer
this question, tumorigenicity of IL-1−/− lines was evaluated in the
immunocompromised host and in vivo growth features were com-
pared with altered gene expression in IL-1α−/−, IL-1β−/−, and IL-
1αβ−/− tumor cells. Our data show that tumorigenicity of IL-1αcomp
tumor lines is unimpaired. In fact, tumor-derived IL-1α contributes
to essential features as anchorage-independent growth and apoptosis
resistance. Nonetheless, IL-1α−/−β comp tumors grow more aggressively,
which is due to augmented inflammatory cytokine and chemokine ex-
pression in IL-1α−/− tumors and a most efficient concomitant stimu-
lation of inflammatory cytokine expression by hematopoietic cells
through tumor-derived IL-1β.
IL-1α and IL-1β Distinctly Support Tumor Growth
and Tumor Cell Survival
Tumor growth in nu/nu mice provided convincing evidence for
unimpaired tumorigenicity of IL-1–deficient fibrosarcoma lines.
However, IL-1β comp tumor lines grew faster and more aggressively
in vivo. One possible explanation could have been that IL-1β pro-
motes tumor cell proliferation and/or strengthens apoptosis re-
sistance, features that actually have been reported to be associated
with membrane-bound and cytoplasmic IL-1α [1,7,8,17,36].
Proliferative activity did not significantly differ between IL-1comp
and IL-1−/− lines, but anchorage-independent growth was strongly
reduced in IL-1α−/− and moderately in IL-1αβ−/− lines. CD44v6
expression is up-regulated in IL-1αcompβ−/− tumor lines. Because
CD44v6 engagement promotes activation of the matrix-associated
protein kinase pathway [37,38], we speculated that high CD44v6 ex-
pression in IL-1αcompβ−/− lines may support anchorage-independent
growth through ERK phosphorylation [39] but ERK phosphorylation
was unaltered. However, TNFRII expression was reduced in IL-1α−/−
lines. Thus, reduced anchorage-independent growth of IL-1α−/− lines
may rely on reduced TNFRII expression and, as a consequence, re-
duced induction of gene expression for cell survival [30,40–42]. Irre-
spective of this remaining open question, our data provide convincing
evidence that anchorage independence is not induced by IL-1α bind-
ing to the IL-1RI, because anti–IL-1RI did not influence the cloning
efficacy of IL-1αcomp lines. In addition, IL-1RI −/− lines displayed a
high cloning efficacy. Nonetheless, a reduction in the lower cloning
efficacy of IL-1β−/− lines by anti–IL-1RI indicates that the minor con-
tribution of IL-1β may be IL-1RI–dependent.
In line with the impaired clonogenicity, drug resistance, too, was
mitigated not only in IL-1α−/− but also in IL-1β−/− lines. Unexpect-
edly, drug resistance was unaltered in IL-1αβ−/− lines. So far, we can-
not explain these findings. CD95 expression was reduced in IL-1α−/−,
IL-1β−/−, and IL-1αβ−/− lines. CD95L and TNFRI expression was not
affected by IL-1 competence. Analyzing mitochondrial pro- and anti-
apoptotic gene expression revealed, corresponding to the unimpaired
apoptosis resistance of IL-1αβ−/− lines, high Bcl2, and proapoptotic
Bax expression. Thus, an IL-1α plus IL-1β deficiency may support
pro- and antiapoptotic protein expression. However, neither in IL-
1α−/−β comp nor in IL-1αcompβ−/− that Bcl2 or Bax expression was
elevated. But Bcl2 expression was reduced in IL-1β−/− lines. It was
variably expressed in IL-1α−/− lines. The reduction in Bcl2 expression
would be in line with the reduced apoptosis resistance of IL-1β−/−
lines. Thus, we evaluated whether Bcl2 may become stabilized in the
IL-1β−/− line by exogeneous IL-1α and/or IL-1β and whether exoge-
neous IL-1α and/or IL-1β may exert a distinct effect on IL-1αβ−/−
lines. Exogeneous IL-1α and/or IL-1β did not support Bcl2 recovery
in the IL-1β−/− line. However, a reduction in Bcl2 was noted in IL-
1αβ−/− cells by exogeneous IL-1β. Conversely, in IL-1αβ comp IL-1RI −/−
cells, addition of IL-1β resulted in an increased Bcl2 recovery. The
finding indicates that in these fibrosarcoma lines, Bcl2 is not regulated
through IL-1RI signaling but may be promoted at the level of pro–
IL-1β, caspase 1, and the inflammosome [43]. Exclusion of the ERK
pathway has already been mentioned, and Akt phosphorylation [44]
and apoptosis-promoting PTEN [45] were variably regulated in
IL-1α−/−, IL-1β−/−, and IL-1αβ−/− lines, which excluded the differ-
ing apoptosis susceptibility/resistance of these lines to be regulated by
the classic PI3K/Akt pathway. Finally, TNFα expression was high in
IL-1α−/−βcomp lines but was lower in IL-1αβ−/− lines, which suggests
that IL-1α actively suppress and IL-1β promote TNFα expression.
Thus, the high TNFα level in the IL-1α−/−β comp lines may account
for the decrease of apoptosis resistance in these lines, whereas lower
TNFα levels in IL-1αβ−/− lines could support unaltered apoptosis re-
sistance [46].
Taken together, our data provide clear evidence that apoptosis re-
sistance of fibrosarcomas is differently regulated by IL-1α and IL-1β.
However, further studies with IL-1 over-expressing tumor lines and
with tumor lines from double knockout mice for IL-1, TNFα,
TNFR, and/or NFκB are required to define the signaling compo-
nents of receptor or mitochondrial apoptosis pathways that account
for distinct apoptosis susceptibility of IL-1α−/−, IL-1β−/−, and IL-
1αβ−/− tumor lines. Irrespective of this open question, the in vitro
analyses on anchorage-independent growth and apoptosis resistance
did not provide a convincing explanation for the more aggressive
growth of IL-1β comp fibrosarcoma lines.
Tumor-Derived IL-1 and the Cross-talk with the
Tumor Stroma
The cross-talk between the tumor and the surrounding stroma
strongly influences tumor growth and progression [47]. IL-1β comp
tumors growing faster, being more efficiently infiltrated by myeloid
cells, and supporting angiogenesis, tumor-derived IL-1β obviously
contributes to creating a tumor growth–favoring milieu. In line
with the in vivo growth features, IL-1β comp tumor lines are more ad-
hesive, display stronger migratory activity, and most strikingly, have
the capacity to grow in cablelike structures on matrigel, which are
considered as morphogenic features related to angiogenesis induc-
tion. In fact, IL-1β comp tumor lines show higher CD51/CD61 and
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slightly increased uPAR expression and more pronounced MMP9
secretion. The stronger adhesiveness of IL-1β comp cells to collagens
and vitronectin also may have contributed to angiogenesis induction
[48]. Increased CD62E expression, which can be supported by IL-1β
[49], may further contribute to the migratory activity of IL-1β comp
lines. Whether higher CD54 and low CD62E expression in IL-1β−/−
lines actively hampers migratory activity [49,50], remains to be ex-
plored. Finally, CXCL10 expression has been described to inhibit
angiogenesis [51]. Notably and in line with increased angiogenesis
induction by IL-1β comp tumor lines, CXCL10 expression was re-
duced in IL-1α−/−β comp tumor lines. On the contrary, it was in-
creased in IL-1αcompβ−/− lines, and it may have actively hampered
angiogenesis induction in these lines. Taken together, adhesion mole-
cule and matrix degrading enzyme expression in IL-1β comp lines are
well in line with promoting the cross-talk between the tumor and
its environment [7,8,17]. Instead, up-regulated CD54 expression
in IL-1αcompβ−/− lines could be counteracting.
Of particular importance for creating a tumor growth–promoting
environment are inflammatory cytokines and chemokines, whose
expressions were increased in IL-1α−/− tumor lines. We interpret
the finding in the sense that in fibrosarcoma lines, possibly distinct
to hematopoietic cells, IL-1α can actively down-regulate inflamma-
tory cytokine and chemokine expression, which is well in line with
cytosolic proIL-1α–influencing gene expression [5,15], but does
not necessarily exclude transcriptional activation by IL-1β. Tumor-
associated IL-1α down-regulation accounted for proinflammatory
cytokines and chemokines involved in the recruitment of myeloid
cells [31]. Instead, expression of the T cell–recruiting cytokines
CCL20 and CXCL10 [32,33] was reduced in IL-1α−/− cells.
Tumor-derived IL-1–dependent differences in chemokine receptor
expression were only observed for CCR7 and CCR6. Low CCR7
expression in IL-1β−/− lines is in line with CCR7 expression mainly
in inflammatory fibroblasts [35]. Conversely, up-regulated CCR7 ex-
pression on IL-1α−/−β comp tumor lines can well promote response to
its ligands, which are, besides others, expressed on lymphatic endo-
thelial cells [52]. Aberrant tumor expression on certain tumor types
has been liked to prosurvival and invasive pathways [52]. CCR6
expression has also been observed in several tumors [34,53] and
IL-1β may contribute to its induction [54]. Whether up-regulated
CCR6 expression, which has been observed particularly in metastatic
tumors [34], in IL-1α−/−β comp lines contributes to their increased tu-
morigenicity remains to be explored.
Our data by no means exclude a contribution of host cells to the
tumor-stroma interaction. However, significant differences being
observed by a selective deficit of IL-1 in the tumor cells argue for
a considerable contribution of tumor-derived IL-1 in initiating and
sustaining its microenvironment. Thus, cytokine/chemokine expres-
sion of IL-1β comp tumor lines obviously supports a high-efficacy an-
giogenesis and the recruitment of myeloid cells into the tumor tissue.
Notably, tumor-derived IL-1α may locally control overshooting in-
flammatory reactions by tumor-derived IL-1β, which could impair
tumor cell survival. However, the cross-talk–supporting activities of
IL-1β are dominating, because IL-1αβ−/− tumor lines do not attract
myeloid cells and do not support angiogenesis.
Tumor-Associated IL-1β and Systemic Inflammation
It recently has come into focus that tumor cells exert systemic ef-
fects that influence the premetastatic organ and the hematopoietic
system. Although cytokines and chemokines are a powerful means
to exert systemic effects [55], it was most surprising and unexpected
that differences in low-level IL-1 expression in fibrosarcoma cells suf-
fice for an induction of a strong systemic response.
Low-level tumor-derived IL-1β strongly induces myelopoiesis
in the immunocompetent [26] and the nude mouse. As described
for the immunocompetent host, most of these myeloid cells are
Gr-1+CD11b+ myeloid-derived suppressor cells [56]. MDSC fre-
quently expand during tumor growth [56,57], and our finding indi-
cates that tumor-derived IL-1β significantly contributes to MDSC
expansion [23,24,26,58,59]. Importantly, too, tumor-derived IL-1β
also sufficed for a systemic induction of an inflammatory cytokine
milieu, which could well affect T cell–mediated immune responses
[60,61]. Notably, cytokine induction in hematopoietic cells differed
from the one within the tumor cell inasmuch as it exclusively
depended on IL-1β, i.e., inflammatory cytokines were not induced
in mice bearing IL-1αcompβ−/− or IL-1αβ−/− tumors. Thus, counter-
regulation of cytokine expression by IL-1α, seen in the tumor cells,
may not account for cells of the hematopoietic system. Nonetheless,
as already mentioned, IL-1 expression in the described fibrosarcoma
lines is very low and does not exceed the one of nonactivated fibro-
blasts. Thus, we hypothesize that additional, not yet defined factors
secreted by IL-1β–expressing fibrosarcoma co-operate with tumor-
derived IL-1β in the induction of an inflammatory milieu. In addi-
tion, IL-1β expression levels in the growing tumor may be higher
than in vitro (R.N. A., unpublished observation), e.g., it is known
that, besides others, hypoxia induces IL-1β transcription [62,63].
Second, although not necessarily, cleavage of pro–IL-1β by caspase-1
can be accompanied by cell death [64], increasing the local concen-
tration of IL-1β and of pro–IL-1β that can also be cleaved by other
proteases, including MMPs [65], which are expressed at an increased
level in IL-1β comp lines. After the recruitment of myeloid cells, which
are a major source of IL-1β [66], Gr-1+CD11b+ cells could well be-
come the initiators of a systemic inflammatory response that can ini-
tiate and sustain the elevated levels of IL-1β at the systemic level
[67]. Gr-1+CD11b+ cells have also been described to promote
IL-10, TNFα, and TGFβ cytokine secretion [56,57,68], with the
expression of these inflammatory cytokines being increased in the
spleen of IL-1β comp tumor-bearing mice.
Taken together, IL-1α and IL-1β have long been suggested to
exert similar functional activity and have been considered as potential
therapeutic drugs [1,6,12,13]. We here demonstrate that tumor-
derived IL-1α is advantageous for the tumor cell itself but hardly
exerts systemic effects in the nu/nu mouse. On the contrary, even
the small amount of tumor-derived IL-1β suffices to promote tumor
cell adhesion and migration and further supports tumor growth by
angiogenesis induction. These features and the strong expansion of
MDSC and the up-regulated expression of inflammatory cytokines
only in mice bearing IL-1β comp tumors suggests that, opposite to
expectation, an efficient interference with tumor-derived IL-1β
may well be of therapeutic benefit. Indeed, increased IL-1β levels
have repeatedly been reported to be associated with poor progno-
sis in cancer patients [69]. Recently, most elegant studies on the
inflammosome system and pharmacological inhibition of IKKβ in
septic shock and multiorgan dysfunction also strengthen the critical
role of IL-1β in systemic inflammation [43,70,71].
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